CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript
CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript
TECH - Bio-Techne Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$65.78
DETAILS
HIGH:
$73.00
LOW:
$50.00
MEDIAN:
$73.00
CONSENSUS:
$65.78
DOWNSIDE:
9.23%
Stock News
CMB.TECH Q2 Earnings Call Highlights
CMB.TECH NYSE: CMBT reported second-quarter 2026 net profit of $364.4 million, supported by revenue of more than $700 million and $127 million in gains from vessel sales, as shipping markets remained strong across several of the company's operating segments.
CMB.TECH ANNOUNCES Q2 2026 RESULTS
ANTWERP, Belgium, 27 August 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2026.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash.Hal
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Bio-Techne and its board of directors violat.
BlackRock Inc. Buys Shares of 14,025,816 Bio-Techne Corp $TECH
BlackRock Inc. purchased a new position in shares of Bio-Techne Corp (NASDAQ: TECH) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,025,816 shares of the biotechnology company's stock, valued at approximately $990,924,000. BlackRock Inc. owned about 8.96% of Bio-Techne
Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders?
Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026
Are PAYO, TECH, CBAN Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.
Bio-Techne Corrects Dividend Announcement
MINNEAPOLIS, Aug. 13, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026.
CMB.TECH ANNOUNCES Q2 2026 RESULTS ON 27/08/2026
ANTWERP, Belgium, 13 August 2026 – CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) will release its second quarter 2026 earnings prior to market opening on Thursday 27 August 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. The half year report will be published on 3 September 2026.
Techne (TECH) Q4 Earnings Meet Estimates
Techne (TECH) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.53 per share a year ago.
Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Bio-Techne beat Wall Street estimates for fourth-quarter revenue on Wednesday helped by growth in its research and diagnostics businesses.
Bio-Techne Declares Dividend
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 17, 2026.
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026. Fourth Quarter FY2026 Highlights Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million.
JAZZ vs. TECH: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
California State Teachers Retirement System Grows Holdings in Bio-Techne Corp $TECH
California State Teachers Retirement System lifted its position in Bio-Techne Corp (NASDAQ: TECH) by 24.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 184,164 shares of the biotechnology company's stock after purchasing an additional 35,772 shares during the quarter. California State
CMB.TECH fleet update
CMB.TECH FLEET UPDATE ANTWERP, Belgium, 3 August 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold one VLCC, generating a capital gain of approximately 74.4 million USD. Euronav CMB.TECH has sold the VLCC Donoussa (2016, 299,999 dwt).
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
Price Targets
Bio-Techne downgraded to Equal Weight from Overweight at Wells Fargo
$73.00
(was $72.22)
Wells Fargo
Bio-Techne downgraded to Equal Weight from Overweight at Stephens
$73.00
(was $71.16)
Steven Etoch
·
Stephens
Bio-Techne price target raised to $73 from $49 at Baird
$73.00
(was $70.70)
Catherine Ramsey Schulte
·
Robert W. Baird
Deutsche Bank Downgrades Bio-Techne Corp. (TECH) to Hold
$73.00
(was $70.70)
Justin Bowers
·
Deutsche Bank
Bio-Techne downgraded to Market Perform from Outperform at Leerink
$73.00
(was $70.55)
Market Perform
·
Leerink Partners
Bio-Techne initiated with a Neutral at Piper Sandler
$65.00
(was $52.50)
Piper Sandler
Bio-Techne resumed with an Outperform at RBC Capital
$62.00
(was $44.74)
RBC Capital
Bio-Techne price target lowered to $50 from $54 at Evercore ISI
$50.00
(was $49.27)
Daniel Markowitz
·
Evercore ISI
Bio-Techne price target lowered to $50 from $65 at Stifel
$50.00
(was $47.41)
Stifel Nicolaus
Bio-Techne price target lowered to $49 from $70 at Baird
$49.00
(was $47.41)
Robert W. Baird
Bio-Techne price target raised to $65 from $60 at Stifel
$65.00
(was $67.64)
Stifel Nicolaus
Bio-Techne price target raised to $79 from $70 at UBS
$79.00
(was $68.67)
UBS
Bio-Techne price target raised to $70 from $61 at Baird
$70.00
(was $68.67)
Robert W. Baird
Bio-Techne downgraded to In Line from Outperform at Evercore ISI
$62.00
(was $59.65)
Evercore ISI
Bio-Techne price target raised to $72 from $66 at Deutsche Bank
$72.00
(was $59.67)
Justin Bowers
·
Deutsche Bank
Bio-Techne price target raised to $68 from $65 at Argus
$68.00
(was $58.64)
Argus Research
Bio-Techne price target lowered to $68 from $72 at Evercore ISI
$68.00
(was $58.40)
Evercore ISI
Bio-Techne upgraded to Outperform at RBC on forecast multiple expansion
$73.00
(was $53.42)
Conor McNamara
·
RBC Capital
Bio-Techne initiated with an Outperform at Evercore ISI
$75.00
(was $62.58)
Evercore ISI
Bio-Techne Corp. (TECH) PT Raised to $84 at Baird
$84.00
(was $76.02)
Catherine Schulte
·
Robert W. Baird